semaglutide and even newer therapies like orforglipron.

The scope of products affected underscores how central GLP-1 RAs have become in modern care. According to the FDA communication, labeling changes will apply to exenatide, liraglutide, liraglutide plus insulin degludec, dulaglutide, lixisenatide plus insulin glargine, semaglutide in all its marketed forms, tirzepatide, and orforglipron. Although the original Byetta new drug application has been withdrawn, generic exenatide versions are still available and fall under the new warning. Reports of NAION have occurred with all currently marketed GLP-1 RA products, which is why the